Abstract

BackgroundIt was reported that tumor heterogeneity and the surrounding tumor microenvironment (TME) in ovarian cancer affects immunotherapy efficacy and patient outcomes. And the TME of ovarian cancer is intrinsically heterogeneous. CD47 plays vital roles in cell functional behavior and immune homeostasis relating to cancer prognosis. But how it affects TME and its contribution to heterogeneity in ovarian cancer has not been fully illustrated. Therefore, we aimed to identify a prognostic biomarker which may help explain tumor immune microenvironment heterogeneity of ovarian cancer.MethodsCancer single-cell state atlas (CancerSEA) was used to evaluate functional role of CD47. Several bioinformatics database including Oncomine, Gene Expression Profiling Interaction Analysis (GEPIA), Tumor Immune Estimation Resource (TIMER), The Human Protein Atlas (HPA), Ualcan and Kaplan-Meier plotter (KM plotter) were applied to illustrate correlation of CD47 with ovarian cancer prognosis and immune infiltration. Tumor Immune Single-cell Hub (TISCH) single cell database was employed to evaluate correlation of CD47 with tumor microenvironment. GeneMANIA was implemented to identify regulation networks of CD47. Differentially expressed genes (DEGs) between CD47 high and low expression groups were analyzed with R package DESeq2. Kyoto encyclopedia of genes and genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) were utilized to explore how CD47 affect the immune related cell signaling pathway.ResultsCD47 expression was upregulated and connected to worse OS and PFS in ovarian cancer. Close relation was found between CD47 expression level and immune infiltration in ovarian cancer, especially with Treg cells, Monocytes, Macrophages and T cell exhaustion (P<0.05). The CD47 expression level was relatively low in plasma cells, dendritic cells and Mono/Macro cells of OV_GSE115007, in myofibroblasts, fibroblasts and endothelial cells of OV_GSE118828, compared to malignant cells of OV_GSE118828 dataset. The cell components and distribution in primary and metastatic ovarian cancer are quite distinct, which may lead to TME heterogeneity of ovarian cancer.ConclusionOur results indicated that CD47 is closely correlated to ovarian cancer immune microenvironment and might induce ovarian cancer heterogeneity. Therefore, CD47 may be used as a candidate prognostic biomarker and provide us with new insights into potential immunotherapy in ovarian cancer patients.

Highlights

  • Ovarian cancer is one of the most lethal malignancies among women worldwide

  • CD47 was highly expressed in bladder urothelial carcinoma (BLCA), BRCA, CESC, cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD) and ovarian cancer (Figure 1B)

  • We found that CD47 mRNA expression level was positively correlated with worse overall survival (OS) among all ovarian cancer patients based on four different arrays (HR=1.16 (1.02-1.33), logrank P=0.025 for 211075_s_at; Hazard ratios (HRs)=1.18 (1.01-1.37), logrank P=0.033 for 213857_s_at; HR=1.33 (1.09-1.63), logrank P=0.0058 for 226016_at and HR = 1.23 (1-1.51), logrank P = 0.048 for 227259_at (Figures 4A–D)

Read more

Summary

Introduction

Ovarian cancer is one of the most lethal malignancies among women worldwide. Even with bulk surgery and adjuvant chemotherapy, it shows a high fatality rate of 70% in late stage patients [1]. Despite advances in maintenance therapy of bevacizumab or PARP inhibitors, most ovarian cancer patients have a high recurrence rate within 5 years of diagnosis [2]. It was reported that immunotherapy efficacy and patient outcomes were closely related to the tumor heterogeneity and the surrounding tumor microenvironment (TME) in ovarian cancer [3, 4]. It was reported that tumor heterogeneity and the surrounding tumor microenvironment (TME) in ovarian cancer affects immunotherapy efficacy and patient outcomes. The TME of ovarian cancer is intrinsically heterogeneous. How it affects TME and its contribution to heterogeneity in ovarian cancer has not been fully illustrated. We aimed to identify a prognostic biomarker which may help explain tumor immune microenvironment heterogeneity of ovarian cancer

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call